- Pathway-based polygenic score analysis identifies the NRF2-
- KEAP1 and mRNA splicing minor pathways as enriched in 2
- shared genetic variation between chronotype and bipolar disorder. 3
- 6 Laura Fahey¹, Lorna M. Lopez¹

4

5

7

8

10

11

12

27

28

29

9 1 Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland

Author Summary

- 13 This study investigates shared genetic influences that may contribute to the circadian rhythm disruption
- 14 and sleep issues in neurodevelopmental and neuropsychiatric conditions. Using polygenic score
- 15 analysis on large-scale genetic studies of autism, attention-deficit/hyperactivity disorder, schizophrenia,
- and bipolar disorder, we tested their ability to predict chronotype and insomnia status of participants in 16
- 17 the UK Biobank. Our findings reveal that polygenic scores for autism, schizophrenia, and bipolar
- disorder are associated with an evening chronotype, while polygenic scores for attention-18
- 19 deficit/hyperactivity disorder, autism, schizophrenia, and bipolar disorder are associated with insomnia.
- 20 Pathway analysis identified the enrichment of shared genetic variation between chronotype and bipolar
- 21 disorder in the NRF2-KEAP1 and mRNA splicing minor pathways. Previous studies have linked the
- 22 NRF2-KEAP1 pathway to the pathology of bipolar disorder and schizophrenia. NRF2 and splicing
- 23 components have been previously reported to be rhythmically regulated by circadian clock genes. These
- 24 results suggest a potential role for the NRF2-KEAP1 and mRNA splicing minor pathways in mediating
- 25 circadian rhythm disturbances in bipolar disorder, providing insights into the genetic basis of sleep
- 26 issues in neuropsychiatric conditions.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 47

48

49

50

51

52

53

54 55

56

57

58

59

Abstract It has been postulated that circadian dysfunction may contribute to the sleep problems prevalent in neurodevelopmental and neuropsychiatric conditions. Genetic correlations between numerous pairs of neurodevelopmental or neuropsychiatric and sleep phenotypes have been identified. We hypothesize that this overlapping genetic variation is enriched in certain biological pathways. We used genome-wide polygenic score analysis to confirm previously reported genetic correlations and pathway-based polygenic score analysis to identify enriched pathways. We created polygenic scores using summary statistics from the largest genome-wide association studies (GWAS) of autism (AUT), attention-deficit/hyperactivity disorder (ADHD), schizophrenia (SCZ) and bipolar disorder (BP). We tested the performance of these polygenic scores in predicting chronotype and insomnia status of UK Biobank participants. For the pathway-based polygenic scores, we restricted genetic variation to SNPs that mapped to genes within 451 pathways from the Reactome database. Genome-wide polygenic scores for AUT, SCZ and BP were found to be associated with an evening chronotype, and polygenic scores for ADHD, AUT, SCZ and BP were found to be associated with insomnia status. Pathway-based polygenic score analysis identified the NRF2 KEAP1 and mRNA splicing minor pathways as being enriched for genetic variation overlapping between chronotype and BP. For the NRF2 KEAP1 pathway, the signal is enriched in the subset of genes that function with KEAP1 to regulate NRF2 expression. Examination of eQTL data pointed to BP associated SNPs within these gene-sets being associated with expression changes of many genes to which they map. A number of these eQTL SNPs were reported to be genome-wide significant for SCZ in previous studies. These results demonstrate that the overlapping genetic variation between chronotype and BP is enriched in genes involved in the NRF2-KEAP1 and mRNA splicing minor pathways. Animal model and human cell line studies have previously linked the NRF2 pathway to the pathology of BP and SCZ. Additionally, NRF2 and splicing components have been reported to be rhythmically regulated by circadian clock genes. Our results suggest that these pathways could be involved in mediating the disrupted circadian rhythm phenotype of BP.

Introduction

60

61

62

63 64

65

66

67 68

69

70 71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

Neurodevelopmental and neuropsychiatric conditions (NDPCs) encompass conditions that affect brain function, cognitive-processes, emotions and behaviour. Neurodevelopmental conditions manifest in childhood, with the most prevalent ones including autism spectrum disorder (AUT) and attention deficit hyperactivity disorder (ADHD) (1). Neuropsychiatric conditions typically have onset in adulthood and include schizophrenia (SCZ) and bipolar disorder (BP). NDPCs are characterised by their symptomatology, with many of them displaying overlapping symptoms. One example of such overlapping symptoms are sleep problems, considered a core symptom in the diagnostic criteria for BP (DSM-5; American Psychiatric Association, 2013), present in up to 80% of individuals with SCZ (3) and AUT (4,5) and observed in up to 50% of those with ADHD (6). Sleep is regulated by sleep/wake homeostasis, which balances the urge to sleep and the requirement for wakefulness. As wakefulness persists, the homeostatic sleep drive intensifies, promoting sleep. Sleep is also regulated by the circadian clock, a biological timing mechanism that is controlled by 24-hour transcription-translational feedback loops involving several core clock genes. The central circadian pacemaker in the suprachiasmatic nucleus (SCN) of the hypothalamus responds to external cues, such as light signals, and synchronizes circadian rhythms across all cells in the body (7). Both sleep/wake homeostasis and circadian rhythm have been shown to be disrupted in NDPCs. Disruption of homeostatic sleep drive, as indicated by reduced slow-wave activity, has been reported in SCZ and early-stage psychosis (8,9). Melatonin and cortisol are two hormones involved in circadian regulation. Melatonin is produced at night, while cortisol is primarily produced in the morning (10). Dysregulation of both hormones has been observed in NDPCs. For example, AUT has being associated with lower levels of melatonin at night (10,11) and ADHD has been associated with lower levels of cortisol after wakening (12). Significant reductions in melatonin levels have also been reported in the cerebrospinal fluid of BP patients (13). Conversely, activities that disrupt circadian rhythms, such as shift work and frequent transatlantic flights, have been associated with adverse mental health (14). Hence, a bidirectional relationship appears to exist, where environmental disruptions to circadian rhythm exacerbate NDPC symptoms, while inherent circadian rhythm disturbances potentially contribute to the development of NDPCs or share underlying mechanisms. This supports the hypothesis that overlapping genetic variation contributes to both circadian disruption and the development of NDPCs. Indeed, mouse models with circadian clock gene mutations display symptoms reminiscent of human NDPCs, with different gene or protein domain mutations resulting in varying sets of NDPC symptoms (15). Genome-wide association studies (GWASs) have identified hundreds of genome-wide single nucleotide polymorphisms (SNPs) associated with different NDPCs and sleep related phenotypes. Chronotype refers to individual's preference for wakening and preforming activity earlier in the day (morning

96

97

98

99

100 101

102

103

104

105

106 107

108

109

110

111

112

113

114

115

116 117

118

119 120

121

122

123

124

125

126

127 128

129

chronotype) or later (evening chronotype). It is a behavioural manifestation of an individual's circadian clock and is often used as a proxy phenotype for circadian timing (16). In modern society, having a morning chronotype is considered advantageous due to its alignment with early school and work start times. Consequently, individuals with an evening chronotype may experience reduced sleep on work/school days and compensate for it on free days - this is known as 'social jetlag' (17). Evening chronotypes have being associated with numerous adverse psychological outcomes (18). The most recent GWAS of a morning chronotype reported enrichment of chronotype associated loci in the clock genes PER1, PER2, PER3, CRY1 and BMAL1. Furthermore, the top enriched biological pathways relate to the circadian clock (19). Surprisingly, no core clock genes have been linked with any NDPC through large-scale GWAS. However, genome-wide correlations in GWAS identified SNP effects have been reported between many sleep traits and NDPCs using the linkage disequilibrium score regression tool (Figure 1). This relationship is negative for the advantageous morning chronotype and positive for insomnia and daytime sleepiness, which are both debilitating. Polygenic score (PGS) analysis can also be used to assess genetic correlations between phenotypes. If a PGS created using effect sizes from a GWAS of one phenotype can significantly predict the phenotype of samples in an independent cohort, it indicates shared genetic variation between the two phenotypes in question (20). PGSs for ADHD and depression have been reported to positively correlate with initiating and maintaining sleep and excessive somnolence in children. Additionally, a PGS for anxiety disorder correlated with nightmares in children (21). These genetic correlation findings suggest that the shared genetic background between NDPCs and circadian rhythms likely extends genome-wide, beyond the core clock genes. Exploring the genes, biological pathways and tissue types impacted by the shared genetic variation between sleep and NDPCs has been a relatively unexplored area. A gene-based cross-trait meta-analysis identified forty-four genes common to both insomnia and ADHD, and found them to be enriched for genes within synaptic-related pathways (22). Another study identified 149 loci shared between psychiatric disorders (SCZ, BP and depression) and sleep traits (chronotype and sleep duration). Fortynine lead SNPs at these loci were found to act as eQTLs for 115 genes across various brain tissues including the basal ganglia, cortex, hippocampus and cerebellum (23). The aims of this study were two-fold. First, we investigated if genome-wide polygenic scores for ADHD, AUT, SCZ and BP could predict insomnia and chronotype in UKB. Secondly, using pathwaybased polygenic score analysis, we investigated the biological pathways implicated by shared genetic variation between these NDPC and sleep phenotypes. We report that polygenic scores for AUT, SCZ and BP were associated with chronotype status and polygenic scores for all four NDPC phenotypes were associated with insomnia. BP polygenic scores, restricted to genetic variation in the KEAP1-NRF2 and mRNA splicing-minor biological pathways were both significant in predicting chronotype, over and above the background signal. To gain further biological insights, we reviewed expression quantitative trait loci data, and found many BP associated SNPs within these gene sets to be associated with expression changes of the genes to which they map.




Figure 1. Published genetic correlations (rg) between pairs of neuropsychiatric or neurodevelopmental and sleep phenotypes. Heatmap cells marked with an asterisk (*) indicate that they were reported as statistically significant in the original publications, after multiple testing correction. The original publications include the latest and largest genome-wide association studies of Autism (AUT; Grove et al., 2019), morning chronotype (Jones et al., 2019), attention-deficit hyperactivity disorder (ADHD; Demontis et al., 2023), bipolar disorder (BP; Mullins et al., 2021), major depressive disorder (MDD; Howard et al., 2019), sleep duration (Dashti et al., 2019) and daytime sleepiness (Wang et al., 2019). Rows and columns are clustered based on similarity.

Results

130

131

132

133

134

135 136

137

138

139

140 141

142

143

144

145

146 147

148

149

Genome-wide polygenic score analysis

To test for indication of shared genetic variation, we investigated if genome-wide polygenic scores for AUT, ADHD, SCZ and BP could predict chronotype and/or insomnia status of UKB participants. We implemented this using the PGS tool, SBayesRC, which re-estimates GWAS SNP effect sizes using a model that incorporates external linkage disequilibrium (LD) and biological annotation data (24). As discovery data for PGS analysis, we used publicly available GWAS summary statistics for the NDPC

150 phenotypes, which were based on studies containing between 46,350 (AUT) and 225,534 (ADHD)

samples. As target data for PGS analysis, we used UKB genotype and questionnaire data related to

chronotype and insomnia. After quality control, we had 409,630 samples with chronotype data and

239,918 samples with insomnia data (see methods).

Polygenic scores for AUT, SCZ and BP, were statistically significant for association with chronotype 154

status (AUT: $r^2 = 3.57 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4} - 4.82 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4} - 4.82 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4} - 4.82 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4} - 4.82 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4} - 4.82 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4} [95\% \text{ CI} = 2.51 \times 10^{-4}], p = <2.20 \times 10^{-16}; \text{ SCZ: } r^2 = 5.13 \times 10^{-4}; \text{ SCZ: } r^2 = 5.13$ 155

 $CI = 3.84 \times 10^{-4} - 6.61 \times 10^{-4}$], $p = <2.20 \times 10^{-16}$; $BP: r^2 = 2.97 \times 10^{-5}$ [95% $CI = 5.71 \times 10^{-6} - 7.25 \times 10^{-5}$], $p = <2.20 \times 10^{-16}$; $P = <2.20 \times 10^{-16}$; P = <2.20156

4.84x10⁻⁴) (Figure 2, Supplementary Table 1). Polygenic scores for all four GWAS phenotypes were 157

statistically significant for association with insomnia, the strongest association being between the

ADHD PGS and insomnia (ADHD: $r^2 = 2.36 \times 10^{-3}$ [95% CI = 1.99×10⁻³ - 2.76×10⁻³], $p = <2.20 \times 10^{-16}$; 159

AUT: $r^2 = 3.69 \times 10^{-5}$ [95% CI = 4.29×10^{-6} - 1.02×10^{-4}], $p = 2.93 \times 10^{-3}$; BP: $r^2 = 1.10 \times 10^{-4}$ [95% CI = 160

 $4.19 \times 10^{-5} - 2.09 \times 10^{-4}$], $p = 2.90 \times 10^{-7}$; SCZ: $r^2 = 3.32 \times 10^{-5}$ [95% CI = $3.07 \times 10^{-6} - 9.52 \times 10^{-6}$], $p = 4.79 \times 10^{-5}$ 161

³; Figure 2; Supplementary Table 1). To enable direct comparison to the pathway PGS analysis in the 162

next section, we also report genome-wide PGSs calculated using the tool, PRSice-2 (Choi & O'Reilly, 163

164 2019), with a P-value threshold of 0.5 (Supplementary Table 1). These results are very similar to those

165 obtained with SBayesRC, with the exception that SBayesRC performed better in the prediction of an

evening chronotype based on all four NDPC PGSs, and also performed better in the prediction of

insomnia based on the ADHD PGS. This improvement is to be expected given that the calculation of

PGSs using LD clumping and p-value thresholding, as in PRSice-2, is not the optimal method for

genome-wide PGS analysis (26). 169

Pathway-based polygenic score analysis

- 171 Pathway-based polygenic score analysis was performed to test if shared genetic variation exists between
- 172 AUT, ADHD, SCZ or BP and chronotype or insomnia status at the biological pathway level. Here, all
- eight pairs of phenotypes were tested, regardless of whether statistically significant results were 173
- 174 observed at the genome-wide level, because it is possible that shared genetic effects are present in
- 175 certain biological pathways, but the effects are too small to be observable at a genome-wide level. We
- tested all Reatome pathways that contained between 50 and 500 genes, resulting in 451 pathways to 176
- 177 test. Pathway-based polygenic scores were derived using SNPs that map by position to each of the 451
- 178 pathways.

151

152

153

158

166

167

168

- Two pathways were statistically significant for the prediction of chronotype status based on BP genetic 179
- variation. These pathways encompass the mRNA splicing minor pathway ($r^2 = 7.5 \times 10^{-5}$ [95% CI = 180
- $3.13 \times 10^{-5} 1.26 \times 10^{-4}$], $P = 3.18 \times 10^{-8}$, competitive $P = 1.33 \times 10^{-5}$) and the KEAP1 NRF2 pathway ($r^2 = 1.33 \times 10^{-5}$) 181
- 7.18×10^{-5} [95% CI = $2.92 \times 10^{-5} 1.33 \times 10^{-3}$], P = 6.26×10^{-8} , competitive P = 1.33×10^{-5} ; Figure 3, 182
- Supplementary Table 2). Note that the competitive P value achieved for each of these significant gene-183
- 184 sets was the lowest possible based on the 75,000 permutations performed. Interestingly, the mRNA

- 185 splicing - minor pathway also ranked the highest, in terms of competitive P value, for the prediction of
- 186 chronotype based on the SCZ PGS, but this did not surpass the multiple testing corrected threshold (r²
- = 5.62×10^{-5} [95% CI = 1.96×10^{-5} - 1.12×10^{-4}], P = 1.65×10^{-6} , competitive P = 1.0×10^{-3} ; Supplementary 187
- 188 Table 2).

196

211

- 189 No pathway PGS achieved a competitive P value that passed multiple testing correction for the
- prediction of insomnia. The pathway Nuclear Events Mediated by NRF2, which is a subpathway of 190
- KEAP1 NRF2, ranked as the second and third highest performing pathways, out of all 451 tested, for 191
- the prediction of insomnia based on SCZ and BP PGSs, respectively (Figure 3, Supplementary Table 192
- 193 3). Competitive P values for the top four pathway PGSs for each of the eight phenotype pairs are
- 194 visualised as a heatmap in Figure 3.

Post-hoc analyses

Interrogations of significant pathway-based polygenic score analysis results

- 197 The mRNA Splicing – Minor Pathway encompasses 50 genes, to which 518 SNPs map, while the
- KEAP1 NRF2 pathway comprises 107 genes, to which 1,356 SNPs map. To explore potential 198
- 199 enrichment of the observed signal within specific subsets of these pathways, we investigated Reactome
- 200 subpathways, some of which were initially omitted due to our criteria of excluding pathways with fewer
- than 50 genes. Given the relatively small size of the mRNA splicing minor pathway, it does not contain 201
- any Reactome subpathways. In contrast, the KEAP1 NRF2 pathway could be broken down into two 202
- 203 Reactome subpathways, and an additional pathway that we established comprising of all genes that do
- 204 not fall into these two subpathways, which we referred to as Regulation of NRF2 by KEAP1. Among
- the KEAP1 NRF2 sub-pathways, the gene-set that explained the most variance was Regulation of NRF2 205
- by KEAP1 ($R^2 = 5.0 \times 10^{-5}$ [95% CI = $1.6 \times 10^{-5} 1.03 \times 10^{-4}$], $P = 6.25 \times 10^{-6}$, competitive $P = 1.87 \times 10^{-4}$; 206
- Figure 4a; Supplementary Table 4). To account for the size of the pathways, we plotted the average 207
- 208 variance in chronotype explained per SNP for these pathway PGSs, in comparison to the average
- 209 variance explained per SNP by a PGS constructed using SNPs that map to all HGNC gene symbols
- 210 (Figure 4b; Supplementary Tables 2 and 4).

eQTL Analysis Results

- 212 To gain a better understanding of the effect of BP genetic variation on the expression of genes within
- 213 the mRNA Splicing – Minor Pathway and KEAP1 NRF2 pathways, we reviewed expression quantitative
- 214 trait loci (eQTLs) data in the database, QTLBase (27). For the KEAP1 NRF2 pathway, five genes
- 215 satisfied the criteria of having gene P values $< 1 \times 10^{-2}$ for BP and $< 1 \times 10^{-3}$ for chronotype based on gene-
- 216 based MAGMA analysis. Of these genes, three contained BP SNPs associated with their expression
- change: cullin-3 (CUL3), proteasome 26S subunit ubiquitin receptor, non-ATPase 2 (PSMD2) and 217
- 218 proteasome 20S subunit beta 10 (PSMB10).

219 CUL3 is a core component of the CUL3-dependent E3 ubiquitin ligase complex which mediates 220 ubiquitination and subsequent degradation of target proteins. This complex associates with KEAP1 to 221 ubiquitinate NRF2, maintaining its abundance at a low level (28) At CUL3, the BP allele of the most 222 significant BP SNP (rs6748341) is associated with decreased expression of CUL3 in the brain cortex (P = 4.91×10^{-6}). Interestingly, a SNP in very high (LD) with this SNP (rs11685299; LD $R^2 = 0.99$) is 223 genome-wide significant for association with SCZ (29). The BP allele of a SNP in high LD with both 224 225 of these SNPs (rs11681451) is also associated with decreased expression of CUL3, this time in three brain regions (Cortex $P = 1.81 \times 10^{-6}$, Hippocampus $P = 1.95 \times 10^{-5}$, Caudate $P = 2.33 \times 10^{-5}$; Supplementary 226 227 Table 5). The gene PSMD2 encodes a subunit of the 26S proteasome, which degrades NRF2 (28). At PSMD2, 228 229 the BP allele of rs843355 is associated with decreased expression of PSMD2 in various immune cells in the blood, including Blood-Neutrophils CD16+ ($P = 1.38 \times 10^{-6}$) and Blood-Monocytes ($P = 1.79 \times 10^{-6}$) 230 231 ⁶) (Supplementary Table 5). 232 Similarly to PSMD2, the PSMB10 gene also encodes a proteasomal subunit involved in NRF2 233 degradation (28). At PSMB10, the BP allele of rs5923 is associated with both increased and decreased 234 expression of PSMB10 in various blood immune cells (Increased: Blood P = 4.2×10^{-9} , Blood-Monocytes CD14+ P = 5.11x10-9, Blood-Neutrophils CD16+ P = 2.94x10-7; Decreased: Blood-Monocytes CD14+ 235 $P = 9.56 \times 10^{-7}$, Blood-Neutrophils CD16+ $P = 8.21 \times 10^{-6}$). 236 For the mRNA Splicing - Minor Pathway, six genes satisfied the criteria of having gene P values < 1x10 237 ² for BP and $< 1 \times 10^{-3}$ for chronotype: splicing factor 3b subunit 1 (SF3B1), splicing factor 3b subunit 1 238 (SF3B2), RNA polymerase II, I And III subunit H (POLR2H), small nuclear ribonucleoprotein U5 239 Subunit 200 (SNRNP200) and pre-mRNA processing factor 6 (PRPF6). 240 SF3B1 encodes subunit 1 of the splicing factor 3b protein complex (SF3b) which is a component of the 241 242 U12 small nuclear ribonucleoprotein (snRNP) of the minor spliceosome and a component of the U2 243 snRNP of the major spliceosome. At SF3B1, the BP allele of the SNP most associated with BP 244 (rs55775495) is associated with increased expression of SF3B in the central nervous system (P = 245 2.68x10-15), peripheral nervous system ($P = 1.13x10^{-6}$), brain cerebellum ($P = 1.30x10^{-6}$) and brain caudate ($P = 2.19 \times 10^{-6}$). Interestingly, the SNP rs6434928, which is in very high LD ($R^2 = 0.88$) with 246 this SNP is genome-wide significant for association with SCZ (30) and has almost the exact same eQTL 247 248 results. SF3B2 encodes subunit 2 of SF3b. The BP allele of rs2270448 is associated with decreased expression of SF3B2 in the brain cerebellum (P = 1.28×10^{-5}). 249 250 POLR2H encodes a subunit shared by the three eukaryotic polymerases. The BP allele of rs62287507 is associated with increased expression of POLR2H in blood (P = 2.33x10⁻⁶). SNRNP200 encodes an 251 RNA helicase that comprises one of the U5 snRNP-specific proteins. At SNRNP200, the BP allele is 252

associated with increased expression in blood neutrophils CD16+ (P = 2.02x10⁻¹¹). PRPF6 encodes a

- 254 protein that acts as a bridging factor between U5 and U4/U6 snRNPs in formation of the spliceosome.
- 255 The encoded protein can also bind androgen receptor, providing a link between transcriptional
- 256 activation and splicing. The BP allele of the most significant SNP at this loci, rs3829704, is associated
- 257 with decreased expression of PRPF6 in blood cells (Lymphocyte $P = 1.29 \times 10^{-31}$, Blood $P = 3.95 \times 10^{-11}$,
- Blood-T cell CD4+ activated P = 1.48x10⁻⁷) and decreased expression of PRPF6 in the brain (Cortex P 258
- 259 $= 1.2 \times 10^{-6}$; Caudate, $P = 6.0 \times 10^{-6}$).

276

277

Differential Expression Analysis

- 261 We next investigated if genes within the mRNA Splicing – Minor Pathway and KEAP1 NRF2 pathway
- 262 are differentially expressed between BP cases and controls. We used PsychEncode differential
- 263 expression data based on postmortem dorsolateral prefrontal cortex samples from 144 BP cases and 899
- 264 healthy controls. Two genes within the mRNA Splicing – Minor Pathway were found to be differentially
- expressed. These are Serine and Arginine Rich Splicing Factor 6 (SRSF6; log2FC = -0.07; P = 2.0x10⁻¹ 265
- ⁴; FDR = 0.01) and Small Nuclear Ribonucleoprotein Polypeptides B and B1 (SNRPB; log2FC = 0.08; 266
- P 4.4x10⁻⁴= FDR = 0.02). Four differentially expressed genes were observed in the KEAP1 NRF2 267
- pathway. These are Sestrin 1 (SESN1; $\log 2FC = 0.07$; $P = 2.8 \times 10^{-4}$; FDR = 0.02), cyclin dependent 268
- kinase inhibitor 1A (CDKN1A log2FC = 0.32; P = 2.51x10⁻⁴; FDR = 0.02), AKT serine/threonine kinase 269
- 1 (AKT1; $\log 2FC = 0.04$; $P = 6.8 \times 10^{-4}$; FDR = 0.03) and MAF BZIP Transcription Factor G (MAFG; 270
- log 2FC = -0.05; $P = 4.9 \times 10^{-4}$; FDR = 0.02). Interestingly, three of these genes are present in Regulation 271
- of NRF2 by KEAP1, which had a higher average R² per SNP than the KEAP1 NRF2 pathway itself 272
- (Figure 4b). However, none of these gene-sets had a statistically significant enrichment of differentially 273
- expressed genes (Regulation of NRF2 by KEAP1 P= 0.09; KEAP1 NRF2 P = 0.5; mRNA Splicing -274
- 275 Minor Pathway P = 0.5).

Discussion

- Using genome-wide polygenic score analysis, we have found that polygenic scores for AUT, SCZ and 278
- BP could predict an evening chronotype and polygenic scores for all four NDPC phenotypes could 279
- 280 predict insomnia status in UKB. Pathway-based polygenic score analysis identified the NRF2 KEAP1
- and mRNA splicing minor pathways as being enriched for genetic variation overlapping between 281
- 282 chronotype and BP. For the NRF2 KEAP1 pathway, the signal is enriched in the subset of genes that
- 283 function with KEAP1 to regulate NRF2 expression. Examination of eQTL data pointed to BP associated
- 284 SNPs being associated with expression changes of many genes within the highlighted pathways to
- 285 which they map. Interestingly, three of the ten eQTL SNPs are genome-wide significant for SCZ
- 286 (Supplementary Table 5).

288

289

290

291

292

293

294

295

296 297

298

299

300

301

302

303

304

305 306

307 308

309

310

311 312

313

314

315

316

317

318

319

320

321

The genome-wide polygenic score results we report support previously published genetic correlation results. AUT and SCZ have previously been reported to exhibit a negative genetic correlation with a morning chronotype, as demonstrated by linkage disequilibrium score regression (31,32). Using a different method and data, our study provides further evidence for these findings, as well as demonstrating a positive association between the BP PGS and an evening chronotype. Additionally, our results confirm that insomnia is genetically correlated with ADHD, SCZ and BP (33–35), the strongest relationship being between ADHD and insomnia. We also report a negative genetic correlation between AUT and insomnia, whereas, in previous studies this relationship was not statistically significant (31). BP polygenic scores created using SNPs that map to the KEAP1 NRF2 and mRNA splicing-minor Reactome pathways were associated with chronotype, over and above the background signal. The majority of the variance explained by the KEAP1 NRF2 gene-set is concentrated within genes belonging to the subpathway, Regulation of NRF2 by KEAP1. It must be noted that the R² values of these pathwaybased PGSs are low. This is partly to be expected, given the small numbers of genes in these pathways. Clear enrichment of explained variance by the mRNA splicing – minor and KEAP1 NRF2 pathways are observed when plotting the average variance explained per SNP for these pathways in comparison to the average variance explained per SNP by PGSs created using all genes based on BP genetic variation (Figure 4b). A sub-pathway of KEAP1-NRF2, Nuclear Events Mediated by NRF2, ranked very highly in predicting insomnia status, based on BP and SCZ genetic variation. This did not reach statistical significance, possibly due there being less insomnia samples (N=239,918) than chronotype samples (N=409,630), and therefore reduced power. NRF2 is a transcription factor that, under normal conditions, is bound by KEAP1 in the cytoplasm as part of the CUL3-KEAP1 E3 ubiquitin ligase complex, which facilitates the ubiquitination of NRF2, marking it for proteasomal degradation. When cells are exposed to oxidative stress, toxins, bacteria, viruses or other forms of cellular damage, KEAP1 cysteine residues are modified, disrupting its binding affinity for NRF2. As a result, NRF2 stabilises and translocates to the nucleus where it binds antioxidant response elements (AREs) in the promoter regions of genes encoding antioxidant enzymes and detoxification proteins (36). Of particular interest regarding sleep and circadian rhythms, NRF2 has also been observed to undergo rhythmic regulation by the two circadian clock genes, BMAL1 and CLOCK, in myeloid cells. These clock genes promote NRF2 expression by binding to the NRF2 E-box domain (37). Through these pathways, NRF2 mediates coupling between oscillations in redox balance and circadian timekeeping mechanisms, with this loop serving to optimise the timing of circadian and seasonal timing of antioxidant responses (38,39). Elevated oxidative stress has been consistently documented in numerous NDPCs (including BP), and this contributes to the concurrent neuroinflammation observed in these conditions (40,41). The increased expression of NRF2 target genes help cells mitigate oxidative stress, improve mitochondrial

323

324

325

326

327 328

329

330

331 332

333 334

335

336

337

338

339

340

341

342

343 344

345

346 347

348

349

350

351 352

353

354 355

356

function and reduce inflammation, all of which are involved in the pathology of NDPCs (36,42). NRF2 also acts as a negative regulator of the NFκB signalling pathway, while the NFκB pathway reciprocally negatively regulates NRF2 signalling. This interaction helps maintain control over basal inflammation and oxidative stress levels (43). When the NRF2 pathway becomes saturated or is deficient, activation of the NFkB pathway is heightened, which leads to an increased production of pro-inflammatory cytokines (36). Given this relationship, it is therefore interesting that the KEAP1 NRF2 and Nuclear Events Mediated by NRF2 pathways clustered together with the FCERI mediated NF-kB activation pathway competitive P value heatmap of the top four pathways across all phenotype pairs (Figure 3). Studies in a seasonal animal model (Meduka fish) that exhibits a constitutive depressive winter phenotype have shown that NRF2 signalling pathways were inactivated in winter photoperiods, and that this was associated with a depressive phenotype that could be reversed by treatment with NRF2 activators (44). These functions of NRF2 signalling in regulating seasonal changes in behaviour are significant since seasonality is such an important clinical feature of human NDPCs. For example, the prevalence of major depressive disorder and seasonal affective disorder show seasonal variation and the oscillations in mood and metabolic function that characterise BP recur with a seasonal rhythm (45). Furthermore, people with BP have higher self-reported seasonality scores (46) and altered sensitivity to changes in day light (47). Chronotype also links seasonality and BP, as evening chronotype is associated with increased self-reported seasonality (48) and with the presence and severity of signs of BD (49). Given the beneficial antioxidant and anti-inflammatory roles of NRF2, it may be hypothesized that NRF2 is downregulated in NDPCs. This was observed in animal models of depression, where lower levels of NRF2 and KEAP1 were reported in the prefrontal cortex and the dentate gyrus and Cornu Ammonis 3 (CA3) regions of the hippocampus, along with increased blood levels of inflammatory cytokines (50). Similar results were seen using human postmortem samples, where protein levels of KEAP1 and NRF2 in the parietal cortex of major depressive disorder, schizophrenia, and bipolar disorder samples were significantly lower than controls. Indeed, there is evidence supporting the potential of natural and synthetic molecules, including melatonin, that elevate NRF2 levels to be used as treatments for psychiatric conditions (36,42). However, there is some disagreement in the literature, with some studies reporting that NRF2 signalling is upregulated in NDPCs. For example, Lukic et al. (2014) reported increased abundance of NRF2, KEAP1, and NF-κB within the cytoplasm of peripheral blood mononuclear cells of MDD patients (51). This lack of consistent direction, in terms of up- or down- regulation of NRF signalling, is reflected in our eQTL results, where BP genetic variation is associated with inconsistent changes in expression of genes within the NRF2 KEAP gene-set. For example, the CUL3 gene encodes the cullin 3 protein, which is a core component of ubiquitin ligase complex which ubiquitinates NRF2 and the PSMD2 gene encodes a subunit of a proteasome that degrades NRF2. Therefore, CUL3 and PSMD2 function together

358

359

360

361

362

363 364

365

366 367

368 369

370

371

372

373

374

375 376

377 378

379

380

381

382

383

384

385

386 387

388

389 390

391

to degrade NRF2, yet BP eQTLs within these genes are associated with expression changes that are in opposite directions. Additionally, the four genes within the NRF2 KEAP1 gene-set that are differentially expressed between BP cases and controls, based on PsychEncode differential expression data, are upregulated. The other pathway highlighted by our study is the mRNA-splicing minor pathway. Splicing of mRNA refers to the removal of introns from pre-mRNA transcripts, a process performed by the spliceosome. The spliceosome comprises distinct complexes responsible for various mRNA splicing steps, composed of both proteins and small nuclear RNAs. While the majority of splicing events are carried out by the major spliceosome, a subset of introns, known as minor introns, necessitates the involvement of the minor spliceosome for their excision (52). Minor splicing is less efficient than major splicing, this reduced efficiency has been proposed to play a role in the regulation of genes containing minor introns, as minor intron containing transcripts are retained in the nucleus until the minor spliceosome components become available. Of relevance to NDPCs, the cerebral cortex is one of the tissues with the highest expression of genes containing minor introns (53). The importance of minor intron splicing is evident by the fact that minor-intron containing genes are highly conserved and thirteen diseases have been linked to mutations in minor splicing components, including the neurodegenerative diseases, amyotrophic lateral sclerosis, and spinal muscular atrophy (52,54,55). A study by Buel and colleagues found oscillations in many components of the major spliceosome pathway mirror that of the clock and bmall transcripts (56), indicating that the major spliceosomal pathway is at least partly regulated by the circadian clock. This is interesting in relation to the minor spliceosome too, given the overlap in these pathways. Interestingly, the biologically related pathway, Processing of Capped Intron-Containing Pre-mRNA, ranked as the second highest performing pathway PGS in the prediction of insomnia based on ADHD genetic variation. This pathway clustered together with mRNA-splicing minor pathway in the heatmap in Figure 3. Neither the NRF2 KEAP1 or the mRNA-splicing minor pathways were found to be enriched in genes differentially expressed between BP cases and controls in the post-mortem dorsolateral prefrontal cortex. It could be that these genes are differentially expressed in a different tissue type to the one we investigated or that the shared genetic variation we have identified only applies to a subset of individuals, and differential expression of these genes would only occur for this subset. A future analysis could select BP cases with high NRF2 KEAP1 / mRNA-splicing minor PGSs and restrict the differential analysis to just these cases (this would require genotype and RNA-sequencing data on BP cases and controls). We implemented MAGMA gene-set analysis to investigate if the NRF2 KEAP1 and mRNA splicing minor pathways could be identified using standard single phenotype pathway enrichment methods. Neither the NRF2 KEAP1 and mRNA splicing minor pathways were enriched for genetic variation perpetuity.

It is made available under a CC-BY 4.0 International license .

392

393

394

395

396

397

398

399

400 401

402

403

404

405

406

407

408

409

410

411412

413

414

415

416

417

418419

420421

422

423

424

individually associated with BP, chronotype or SCZ (Supplementary Table 6). This indicates that these pathways are enriched for the genetic variation shared between these two phenotypes and are not enriched for the genetic variation associated with each individual phenotype. There are some limitations to the pathway-based PGS method we have implemented. Firstly, we mapped SNPs to genes solely based on the physical distance of SNPs to genes. While, it has been reported that the majority (76%) of GWAS SNPs affect the closest gene (57), SNPs can be located in regulatory elements up to hundreds of megabases away from the causal gene. Such distal causal genes were not included in our analysis. Another limitation is that polygenic score analysis cannot distinguish between horizontal versus vertical pleiotropy i.e. whether genetic variation within the NRF2 KEAP1 and mRNA splicing minor pathways independently contribute to both BP and an evening chronotype, or whether genetic variation within these pathways contribute to an evening chronotype, which in turn, causes BP, or vice versa. This is the first study to investigate the biological pathways enriched in genetic variation overlapping between NDPC and sleep phenotypes, using pathway-based PGS analysis in a global, rather than hypothesis-based design. We used the largest available datasets from GWASs of ADHD, AUT, BP as our discovery datasets, and our target dataset consisted of up to 409,630 samples from UKB. Our findings of shared genetic variation between chronotype and BP in a pathway that is known to regulate circadian rhythms and seasonality in animals (NRF2 KEAPI) in addition to the strongly seasonal nature of the clinical features and prevalence of BP, are further evidence to support the hypothesis that disrupted circadian rhythm and seasonal adaptive responses underlie the pathology of BP (58). Furthermore, our findings highlight the mRNA splicing-minor pathway, which has also been shown to be at least partly regulated by the circadian clock. Thus, this study provides further evidence to support the circadian clock hypothesis of BP disorder. Methods Target Data for Polygenic Score Analysis – UK Biobank **Quality Control (QC)** Genotype data was collected, processed and imputed by UKB (59). We accessed and analysed the data through the UKB Research Analysis Platform (Application ID: 71469). UKB research participants were excluded based on the following criteria: not being of Caucasian ancestry (data-field: 22006),

containing a sex chromosomal aneuploidy (data-field: 22019), having a high SNP missingness and/or

having unusually high or low heterozygosity (data-field: 22027), having ten or more third-degree

relatives (data-field: 22021) and performing shift work (data-field: 826). Further samples were removed

426

427

428 429

430

431

432 433

434 435

436 437

438 439

440

441

442

443 444

445

446

447

448

449 450

451 452

453 454

455 456

457

458

based on relatedness using the UKB supplied relatedness file, which lists pairs of individuals related up to a third degree. One individual from each pair was removed without removing samples from pairs where a sample had already been removed. A total of 487,409 samples passed these quality control measures. To minimize any potential overlap between UKB and PGC SCZ and BP cohorts, participants who had received SCZ or BP diagnoses were excluded from the construction of the SCZ PGS or BP PGS, respectively. Such samples were identified through self-reported diagnoses (data-field: 20544) and linked health records reporting international classification of disease (ICD10) codes, F200-F209 for SCZ and F310-F319 for BP (data-field: 41270). This resulted in a further removal of 1,223 SCZ samples and 1,866 BP samples, in the construction of the SCZ and BP PGSs, respectively. SNPs were excluded based on the following criteria: imputation quality score (INFO) < 0.7, proportion of missing genotypes > 0.02, minor allele frequency (MAF) < 0.005, Hardy-Weinberg equilibrium (HWE) < 1×10⁻⁶. Duplicate SNPs were removed using Plink2 with the flag "--rm-dup force-first". Plink2 binary file-sets were created using the "--make-bed" flag and chromosome specific files were merged using the Plink2 "--merge-list" flag. Finally, ambiguous SNPs and SNPs not present in the corresponding neuropsychiatric GWAS were removed. **Phenotype Generation** Two UKB phenotypes were used for this study: chronotype ("Morning/evening person (chronotype)"; data-field 1180) and insomnia ("sleeplessness/insomnia"; data-field 1200). These data points were gathered as part of a questionnaire participants completed on touchscreen computers at UKB assessment centres. For chronotype, participants were asked the question, "do you consider yourself to be"?, and they had six optional answers, which we encoded as a quantitative eveningness phenotype: "Definitely an 'evening' person" was encoded as 4, "More an 'evening' than a 'morning' person" was encoded as 3, "More a 'morning' than an 'evening' person" was encoded as 2, "Definitely a 'morning' person" was encoded as 1, "Prefer not to answer" and "Do not know" were both encoded as missing. This resulted in 409,630 post-QC samples with chronotype data. For insomnia, participants were asked the question, "do you consider yourself to be"? and had four optional answers, which we encoded in a binary fashion: "never/rarely" was encoded as 0, "usually" was encoded as 1 and "sometimes" and "Prefer not to answer" were both encoded as missing. This resulted in post-QC 239,918 samples with insomnia data. **Correcting for Confounders**

The UKB phenotypes were corrected for the effects of confounders by taking the residuals of regression models with the UKB phenotype as the dependent variable and the confounders as the independent variables. For the binary insomnia phenotype, a logistic regression model was used, while a linear

459 regression model was used for the quantitative chronotype phenotype. The residuals of these models, 460 representing the variation in phenotype left unexplained by the effects of confounders, were assigned 461 as the corrected phenotypes. The fourteen confounders corrected for were: age, sex, UKB assessment centre, genotyping batch and genetic principal components (PCs) 1-10. 462

Discovery Data for Polygenic Score Analysis – GWAS Summary Statistics

- Discovery data for polygenic score analysis included summary statistics from the latest and largest 464
- published GWAS of AUT (18,381 cases and 27,969 controls from a Danish population (31)), ADHD 465
- (38,691 cases and 186,843 controls from European, Danish and Icelandic populations (33)), SCZ 466
- 467 (74,776)101,023 controls from and European, East
- 468 African American and Latino populations (30)) and BP (41,917 cases and 31,358 controls from a
- 469 European population (35)).

463

470

Genome-Wide Polygenic Score Analysis

- 471 Effect sizes for all imputed SNPs were estimated using SBayesRC based on GWAS summary statistics.
- 472 SBayesRC models SNP effects using a mixture of normal distributions that differ in their variances and
- 473 uses SNP annotation information to select which of these distributions best model SNP effect sizes.
- 474 This allows for SNP effect probability distributions to differ across annotation groups and has been
- 475 shown to perform better than other popular PGS methods (24). Inputs to SBayesRC include GWAS
- 476 summary statistics, LD European reference data and data containing 96 functional annotations for 8
- 477 million imputed **SNPs** (the latter two data files were downloaded from
- 478 github.com/zhilizheng/SBayesRC)
- 479 The first step involves converting GWAS summary statistics to COJO format, and converting odds
- 480 ratios to beta values using log(OR) when beta values were not provided. Subsequently, the SBayesRC
- 481 tidy function was run to filter SNPs based on inconsistent alleles between the GWAS summary statistic
- 482 and LD data and per SNP sample sizes less than three standard deviations of the mean. The SBayesRC
- impute function was implemented to impute the GWAS summary data based on LD. This resulted in 483
- 7,356,519 SNPs for each phenotype. The main SBayesRC function was then run to estimate SNP 484
- 485 effects. These SNP effects were provided to the --score command in Plink1.9 to calculate PGSs for all
- 486 individuals in the UKB test dataset (60). Performance metrics were calculated in R by running linear
- regressions with UKB chronotype or insomnia status as the dependent variable and the SCZ, BP, AUT 487
- or ADHD PGS as the independent variables. P values and variance explained (R²) were obtained using 488
- 489 R's summary function. Confidence intervals were created using the ci rsquared function as part of the
- 490 confintr R package (https://github.com/mayer79/confintr).

Pathway-Based Polygenic Score Analysis

Pathway data

491

492

498

- 493 Pathway data for pathway based PGS analysis was sourced from Reactome, an open-source, manually
- 494 curated and peer-reviewed pathway database (61). We used all Homo sapien pathways that contained
- 495 greater than 50 genes, to remove overly specific pathways, and less than 500 genes, to remove overly
- broad pathways and limit the computational intensity of pathway-based PGS analysis. This resulted in 496
- 497 451 pathways to test.

Pathway-based polygenic score analysis using PRSet

- 499 Polygenic score analysis was performed using the tool, PRSet (62). Inputs to PRSet included Reactome
- 500 pathway data, published GWAS summary statistics to be used as discovery data, UKB files in PLINK
- 501 binary format (.bed, .bim and .fam) to be used as target data and a GTF file for the genome build,
- GRCh37. SNPs with a reported P > 0.5 from the corresponding GWAS were removed. This resulted in 502
- 503 final SNP numbers of N = 2.374.077 for the AUT PGS, N = 2.187.591 for the ADHD PGS, N = 2.187.591
- 504 2,525,546 for the SCZ PGS and N = 2,416,496 for the BP PGS.
- Pathway-based PGS analysis in PRSet involves three steps. The first step is to map SNPs to genes by 505
- 506 genomic position using GRCh37 start-stop coordinates extended 35kb upstream and 10kb downstream
- 507 to include potential regulatory elements. The second step is to perform pathway specific LD clumping
- 508 (parameters used: --clump-kb 250kb --clump-p 1 --clump-r2 0.1). Clumping is performed for each
- 509 pathway independently to retain the genetic signal for each pathway i.e to prevent a SNP outside of the
- pathway being assigned as the lead clumped SNP. The third step involves calculating pathway specific 510
- PGSs for each individual, by summing up, for each SNP, the number of minor alleles at that SNP 511
- multiplied by the GWAS effect size. Finally, performance metrics (R² and P value) are calculated for 512
- 513 each pathway. Competitive analysis was performed by creating 5,000 background polygenic scores,
- each constructed by randomly sampling the same number of post LD clumped SNPs as contained within 514
- gene-set being tested and conservatively including the gene-set being tested as one background set. A 515
- 516 competitive P value is created using a formula that counts the number of times the P value for a
- background gene-set is less than the P value for the gene-set being tested and dividing by the number 517
- 518 of permutations (62). A disadvantage of this method is that the lowest possible P value is 1 / (number
- 519 of permutations + 1). Therefore, gene-sets that reached the lowest possible competitive P value at 5,000
- 520 permutations were re-analysed with a higher number of permutations. Confidence intervals were
- 521 calculated for the top performing pathways in R using the same method as for the genome-wide PGSs.
- 522 Multiple testing correction was performed for pathway-based PGS analysis by calculating a Bonferroni
- 523 corrected P value threshold, where 0.05 was divided by the number of tests performed (four GWAS
- 524 phenotypes x 451 pathways x 2 UKB phenotypes = 3,608).

Post-hoc analysis

525

526

527

528

529 530

531

532 533

534

535

536

537

538

539

540

541

544

545

546 547

548 549

550

551

552

553

554

555

556

557

MAGMA gene-set analysis

Gene-sets that were statistically significant in the PGS analysis, and the genes within them, were tested for enrichment of common genetic variation using region-based multi-marker analysis of genomic annotation (MAGMA; http://ctg.cncr.nl/software/magma; (63) and summary statistics from published GWAS on chronotype (69,369 cases and 236,642 controls of British ancestry; 3) and BP. An analysis involves three steps. First, in the annotation step, SNPs with available GWAS results are mapped on to genes (GRCh37/hg19 start-stop coordinates +35kb/-10kb). Second, in the gene analysis step, gene P values are computed for each GWAS dataset. This gene analysis is based on a multiple linear principal components regression model that accounts for LD between SNPs in each gene, number of SNPs in each gene, inverse of the mean minor allele count of variants in each gene and the GWAS sample size. The European panel of the 1000 Genomes data was used as a reference panel for LD. Third, a competitive GSA based on the gene P values, also using a regression structure, was used to test if the genes in each gene-set were more strongly associated with either phenotype than other genes in the genome.

eQTL Analysis

542 Expression quantitative trait loci (eQTL) data was examined using QTLbase2 (27), a database that 543 aggregates published genome-wide QTL summary statistics across more than 95 tissue and cell types.

We reviewed eQTL data related to genes found within the gene-sets prioritised by pathway-based PGS

analysis. Specifically, we considered genes that achieved significance levels of $P < 1 \times 10^{-2}$ for BP and P

 $< 1 \times 10^{-3}$ for chronotype in the gene-based MAGMA analysis. This was to identify genes individually

enriched for BP and chronotype genetic variation, as these are the genes most likely contributing to the

significant pathway-based PGS results and therefore of interest. Since these genes were already highlighted as being of interest through pathway-based PGS analysis, it was not necessary that they

were individually statistically significant in the MAGMA analysis.

The most statistically significant SNP at each gene locus was searched in QTLbase to identify if it had been associated with expression changes of the mapped gene in biologically relevant tissues or cell types, including those related to the brain, central nervous system, peripheral nervous system, blood, or immune systems. If the top SNP at a locus did not show any eQTL associations, we investigated other SNPs with similarly low P values at that locus. It was assumed that the SNPs demonstrating the highest statistical significance for association with BP would also contribute to chronotype prediction, given that BP effect sizes were used to compute the pathway-based PGSs.

Differential Expression Analysis

- 559 Differential expression summary data was downloaded as Supplementary Table 1 from Gandal et al.
- 560 (2018). This is a PsychENCODE Consortium study that performed RNA-sequencing, followed by
- differential expression analysis, of samples isolated form the postmortem dorsolateral prefrontal cortex 561
- samples for 144 BP cases and 899 controls. Specific details of the analysis performed are provided in 562
- 563 the paper (64)

558

566

571

572

- More specific methodology details and code for all analyses are provided here: 564
- 565 https://github.com/laurafahey02/ Polygenic Score Analyses.

Acknowledgements

- 567 This project has received funding from the European Research Council (ERC) under the European
- Union's Horizon 2020 research and innovation programme (grant agreement No 950010). We would 568
- 569 like to thank Dr Cathy Wyse for discussions related to chronobiology and for reviewing a draft of the
- 570 manuscript.

Bibliography

- Scandurra V, Emberti Gialloreti L, Barbanera F, Scordo MR, Pierini A, Canitano R. 573 1.
- 574 Neurodevelopmental Disorders and Adaptive Functions: A Study of Children With
- Autism Spectrum Disorders (ASD) and/or Attention Deficit and Hyperactivity Disorder 575
- (ADHD). Front Psychiatry. 2019;10:673. 576
- 577 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
- Disorders. American Psychiatric Association; 2013. 578
- 3. Cohrs S. Sleep Disturbances in Patients with Schizophrenia. CNS Drugs. 579
- 2008;22(11):939–62. 580
- 581 4. Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum
- disorder. Sleep Med. 2010 Aug;11(7):659-64. 582
- 5. Galli J, Loi E, Visconti LM, Mattei P, Eusebi A, Calza S, et al. Sleep Disturbances in 583
- Children Affected by Autism Spectrum Disorder. Front Psychiatry. 2022 Feb 17;13. 584
- 6. Wajszilber D, Santisteban JA, Gruber R. Sleep disorders in patients with ADHD: impact 585
- 586 and management challenges. Nat Sci Sleep. 2018 Dec; Volume 10:453-80.

7. 587 Deboer T. Sleep homeostasis and the circadian clock: Do the circadian pacemaker and 588 the sleep homeostat influence each other's functioning? Neurobiol Sleep Circadian 589 Rhythms. 2018 Jun;5:68-77. 8. 590 Zhang Y, Quiñones GM, Ferrarelli F. Sleep spindle and slow wave abnormalities in 591 schizophrenia and other psychotic disorders: Recent findings and future directions. 592 Schizophr Res. 2020 Jul;221:29-36. 593 9. D'Agostino A, Castelnovo A, Cavallotti S, Casetta C, Marcatili M, Gambini O, et al. 594 Sleep endophenotypes of schizophrenia: slow waves and sleep spindles in unaffected first-degree relatives. NPJ Schizophr. 2018 Feb 9;4(1):2. 595 596 10. Alachkar A, Lee J, Asthana K, Vakil Monfared R, Chen J, Alhassen S, et al. The hidden 597 link between circadian entropy and mental health disorders. Transl Psychiatry. 2022 Jul 598 14;12(1):281. 599 Logan RW, McClung CA. Rhythms of life: circadian disruption and brain disorders 11. across the lifespan. Nat Rev Neurosci. 2019 Jan;20(1):49-65. 600 601 12. Coogan AN, McGowan NM. A systematic review of circadian function, chronotype and 602 chronotherapy in attention deficit hyperactivity disorder. ADHD Attention Deficit and 603 Hyperactivity Disorders. 2017 Sep 7;9(3):129-47. Bumb JM, Enning F, Mueller JK, van der List T, Rohleder C, Findeisen P, et al. 604 13. 605 Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Compr Psychiatry. 2016 Jul;68:34-9. 606 Brown JP, Martin D, Nagaria Z, Verceles AC, Jobe SL, Wickwire EM. Mental Health 607 14. Consequences of Shift Work: An Updated Review. Curr Psychiatry Rep. 2020 Feb 608 609 18;22(2):7. 610 15. von Schantz M, Leocadio-Miguel MA, McCarthy MJ, Papiol S, Landgraf D. Genomic perspectives on the circadian clock hypothesis of psychiatric disorders. In 2021. p. 153– 611 612 91. 613 16. von Schantz M. Natural Variation in Human Clocks. In 2017. p. 73–96. 614 17. Roenneberg T. How can social jetlag affect health? Nat Rev Endocrinol. 2023 Jul 23;19(7):383-4. 615

616

617

18.

Zou H, Zhou H, Yan R, Yao Z, Lu Q. Chronotype, circadian rhythm, and psychiatric

disorders: Recent evidence and potential mechanisms. Front Neurosci. 2022;16:811771.

618 19. Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-619 wide association analyses of chronotype in 697,828 individuals provides insights into 620 circadian rhythms. Nat Commun. 2019 Dec 29;10(1):343. 621 20. Mistry S, Harrison JR, Smith DJ, Escott-Price V, Zammit S. The use of polygenic risk 622 scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic review. Schizophr Res. 2018 Jul;197:2-8. 623 624 21. Ohi K, Ochi R, Noda Y, Wada M, Sugiyama S, Nishi A, et al. Polygenic risk scores for major psychiatric and neurodevelopmental disorders contribute to sleep disturbance in 625 childhood: Adolescent Brain Cognitive Development (ABCD) Study. Transl Psychiatry. 626 627 2021;11(1):187. 628 22. Carpena MX, Bonilla C, Matijasevich A, Martins-Silva T, Genro JP, Hutz MH, et al. 629 Sleep-related traits and attention-deficit/hyperactivity disorder comorbidity: Shared 630 genetic risk factors, molecular mechanisms, and causal effects. The World Journal of Biological Psychiatry. 2021 Nov 26;22(10):778-91. 631 632 23. O'Connell KS, Frei O, Bahrami S, Smeland OB, Bettella F, Cheng W, et al. Characterizing the Genetic Overlap Between Psychiatric Disorders and Sleep-Related 633 Phenotypes. Biol Psychiatry. 2021 Nov;90(9):621-31. 634 635 24. Zheng Z, Liu S, Sidorenko J, Yengo L, Turley P, Ani A, et al. Leveraging functional genomic annotations and genome coverage to improve polygenic prediction of complex 636 637 traits within and between ancestries. bioRxiv [Internet]. 2022 Jan 1;2022.10.12.510418. Available from: http://biorxiv.org/content/early/2022/10/14/2022.10.12.510418.abstract 638 639 25. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. 640 Gigascience. 2019 Jul 1;8(7). 641 26. Ni G, Zeng J, Revez JA, Wang Y, Zheng Z, Ge T, et al. A Comparison of Ten Polygenic 642 Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. Biol Psychiatry. 2021 Nov 1;90(9):611-20. 643 644 27. Zheng Z, Huang D, Wang J, Zhao K, Zhou Y, Guo Z, et al. QTLbase: an integrative resource for quantitative trait loci across multiple human molecular phenotypes. Nucleic 645 Acids Res. 2020 Jan 8;48(D1):D983-91. 646 647 28. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The 648 GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr

Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33.

650 29. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. 651 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature.

- 652 2022 Apr 21;604(7906):502-8.
- 653 30. Trubetskov V, Pardiñas AF, Oi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.
- 654 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature.
- 2022 Apr;604(7906):502-8. 655
- 31. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of 656
- 657 common genetic risk variants for autism spectrum disorder. Nat Genet. 2019 Mar
- 658 25;51(3):431-44.
- Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-659 32.
- 660 wide association analyses of chronotype in 697,828 individuals provides insights into
- 661 circadian rhythms. Nat Commun. 2019 Jan 29;10(1):343.
- 33. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of 662
- the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat 663
- 664 Genet. 2019 Jan 26;51(1):63-75.
- Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Agee M, et al. Genome-665 34.
- wide meta-analysis of insomnia prioritizes genes associated with metabolic and 666
- psychiatric pathways. Nat Genet. 2022 Aug 14;54(8):1125–32. 667
- Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. 668 35.
- Genome-wide association study of more than 40,000 bipolar disorder cases provides new 669
- 670 insights into the underlying biology. Nat Genet. 2021 Jun 17;53(6):817–29.
- 671 36. Bhandari R, Kaur J, Kaur S, Kuhad A. The Nrf2 pathway in psychiatric disorders:
- pathophysiological role and potential targeting. Expert Opin Ther Targets. 2021 Feb 672
- 1;25(2):115-39. 673
- 674 37. Early JO, Menon D, Wyse CA, Cervantes-Silva MP, Zaslona Z, Carroll RG, et al.
- Circadian clock protein BMAL1 regulates IL-1β in macrophages via NRF2. Proc Natl 675
- Acad Sci U S A. 2018 Sep 4;115(36):E8460-8. 676
- 38. Wible RS, Ramanathan C, Sutter CH, Olesen KM, Kensler TW, Liu AC, et al. NRF2 677
- 678 regulates core and stabilizing circadian clock loops, coupling redox and timekeeping in
- 679 Mus musculus. Elife. 2018 Feb 26;7.

680 39. Tamaru T, Hattori M, Ninomiya Y, Kawamura G, Varès G, Honda K, et al. ROS Stress 681 Resets Circadian Clocks to Coordinate Pro-Survival Signals. PLoS One. 2013 Dec 682 2;8(12):e82006.

- 683 40. Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int 684 J Mol Sci. 2022 May 25;23(11). 685
- 41. Salim S. Oxidative stress and psychological disorders. Curr Neuropharmacol. 2014 686 687 Mar;12(2):140-7.
- 688 42. Morris G, Walker AJ, Walder K, Berk M, Marx W, Carvalho AF, et al. Increasing Nrf2 689 Activity as a Treatment Approach in Neuropsychiatry. Mol Neurobiol. 2021 690 May;58(5):2158-82.
- 43. Gao W, Guo L, Yang Y, Wang Y, Xia S, Gong H, et al. Dissecting the Crosstalk 691 692 Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity. Front Cell Dev Biol. 2022 Feb 2;9. 693
- Nakayama T, Okimura K, Shen J, Guh YJ, Tamai TK, Shimada A, et al. Seasonal 694 44. 695 changes in NRF2 antioxidant pathway regulates winter depression-like behavior. 696 Proceedings of the National Academy of Sciences. 2020 Apr 28;117(17):9594–603.
- Geoffroy PA, Bellivier F, Scott J, Etain B. Seasonality and bipolar disorder: A systematic 697 45. 698 review, from admission rates to seasonality of symptoms. J Affect Disord. 2014 699 Oct;168:210-23.
- 700 Reynaud E, Berna F, Haffen E, Weiner L, Maruani J, Lejoyeux M, et al. Validity and 46. 701 Usage of the Seasonal Pattern Assessment Questionnaire (SPAQ) in a French Population 702 of Patients with Depression, Bipolar Disorders and Controls. J Clin Med. 2021 Apr 703 27;10(9):1897.
- Roguski A, Ritter P, Smith DJ. Sensitivity to light in bipolar disorder: implications for 704 47. 705 research and clinical practice. The British Journal of Psychiatry. 2024 Jan 4;1–4.
- 706 48. Bjorvatn B, Saxvig IW, Waage S, Pallesen S. Self-reported seasonality is strongly associated with chronotype and weakly associated with latitude. Chronobiol Int. 2021 707 708 Feb 1;38(2):278–85.
- 709 49. Menculini G, Steardo LJr, Verdolini N, D'Angelo M, Chipi E, Cirimbilli F, et al. 710 Chronotype is associated with affective temperaments, clinical severity and worse

711 treatment outcomes in bipolar disorders: results from a two-center, cross-sectional study. 712 Int J Psychiatry Clin Pract. 2023 Sep 1;27(3):248–56.

- 713 50. Hashimoto K. Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and 714 Future Perspective. Front Pharmacol. 2018;9:1182.
- 715 Lukic I, Mitic M, Djordjevic J, Tatalovic N, Bozovic N, Soldatovic I, et al. Lymphocyte 51. 716 levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients. Neuropsychobiology. 2014;70(1):1–9. 717
- 718 52. El Marabti E, Malek J, Younis I. Minor Intron Splicing from Basic Science to Disease. 719 Int J Mol Sci. 2021 Jun 4;22(11):6062.
- 720 53. Olthof AM, Hyatt KC, Kanadia RN. Minor intron splicing revisited: identification of new 721 minor intron-containing genes and tissue-dependent retention and alternative splicing of 722 minor introns. BMC Genomics. 2019 Dec 30;20(1):686.
- 723 54. Reber S, Stettler J, Filosa G, Colombo M, Jutzi D, Lenzken SC, et al. Minor intron 724 splicing is regulated by <scp>FUS</scp> and affected by <scp>ALS</scp> -associated <scp>FUS</scp> mutants. EMBO J. 2016 Jul 15;35(14):1504–21. 725
- 726 55. Jangi M, Fleet C, Cullen P, Gupta S V., Mekhoubad S, Chiao E, et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA 727 728 damage. Proceedings of the National Academy of Sciences. 2017 Mar 21;114(12).
- 729 56. Buel SM, Debopadhaya S, De los Santos H, Edwards KM, David AM, Dao UH, et al. 730 The PAICE suite reveals circadian posttranscriptional timing of noncoding RNAs and 731 spliceosome components in Mus musculus macrophages. G3 Genes|Genomes|Genetics. 732 2022 Aug 25;12(9).
- Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, et al. 733 57. Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021 734 May:593(7858):238-43. 735
- 736 58. McCarthy MJ, Gottlieb JF, Gonzalez R, McClung CA, Alloy LB, Cain S, et al. 737 Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi-disciplinary literature review and agenda for future research 738 739 from the ISBD task force on chronobiology. Bipolar Disord. 2022 May 10;24(3):232-63.
- 740 59. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank 741 resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203-9.

743

744

745

746

747 748

749

750

751

752

753

754

755

60. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. The American Journal of Human Genetics. 2007 Sep;81(3):559–75. 61. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018 Jan 4;46(D1):D649-55. 62. Choi SW, García-González J, Ruan Y, Wu HM, Porras C, Johnson J, et al. PRSet: Pathway-based polygenic risk score analyses and software. PLoS Genet. 2023 Feb;19(2):e1010624. 63. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015 Apr;11(4):e1004219. 64. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptomewide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018 Dec 14;362(6420).




Figure 2. Genome-wide polygenic score analysis results. Linear regressions were run with UK Biobank chronotype or insomnia status as the dependent variable and SCZ, BP, AUT or ADHD polygenic score as the independent variables. UK Biobank phenotypes were corrected for sex, genotyping batch, UK Biobank assessment centre and the top ten ancestry-informative genetic principal components prior to running this regression. Horizontal bars show the variance explained (R^2), error bars indicate 95% confidence intervals. Bars marked with an asterisk (*) indicate that they surpass the Bonferroni-corrected p value threshold of $p \le 0.0001$.




Figure 3. Top performing pathways from pathway-based polygenic score analysis. Performance metrics for pathway-based polygenic score analysis were calculated by regressing insomnia or chronotype case status on each of the pathway-based polygenic scores. Competitive P values were calculated by creating at least 5,000 background polygenic scores, consisting of random sets of post-clump SNPs, the same size as the pathway under test (in this way, pathway size is controlled for). The competitive P value takes into account the number of times a background gene-set obtains a lower null P value than the pathway being tested. The four pathways that resulted in the lowest competitive P values for each of the eight phenotype pairs were identified, and their competitive P values across each of the eight phenotype pairs were plotted as a heatmap. The white stars represent pathway based polygenic scores statistically significant after multiple testing correction ($P < 1.39 \times 10^{-5}$). Rows are clustered based on similarity.




Figure 4. Variance explained (R^2) by the statistically significant pathway-based BP PGSs, and their subpathways, in predicting chronotype. Bars marked with an asterisk (*) indicate that they surpass the Bonferroni-corrected P value threshold of $P \le 1.39 \times 10^{-5}$. A) Total variance explained per pathway. Horizontal bars show the variance explained (R^2), error bars indicate 95% confidence intervals. B) Average variance explained per SNP. This was obtained by dividing the total variance explained per pathway by the number of SNPs in that pathway.